You are here

Article Text

Article menu
Download PDFPDF
Editorial
Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition

https://doi.org/10.1136/thoraxjnl-2016-208680

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Interstitial lung disease
      Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
      Paul F Mercer Hannah V Woodcock Jessica D Eley Manuela Platé Michal G Sulikowski Pascal F Durrenberger Linda Franklin Carmel B Nanthakumar Yim Man Federica Genovese Robin J McAnulty Shuying Yang Toby M Maher Andrew G Nicholson Andy D Blanchard Richard P Marshall Pauline T Lukey Rachel C Chambers
      Thorax 2016; 71 701-711 Published Online First: 21 Apr 2016. doi: 10.1136/thoraxjnl-2015-207429
    • Airwaves
      Highlights from this issue
      BMJ Publishing Group Ltd and British Thoracic Society
      Thorax 2016; 71 i-i Published Online First: 14 Jul 2016. doi: 10.1136/thoraxjnl-2016-209100